B5H7, a Morpholine Derivative of 23-Hydroxybetulinic Acid, Reverses Doxorubicin Resistance in HepG2/ADM

Authors

  • Nan Yao College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Dao-Lu Liu College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Ying-Jie Li College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Zhe-Sheng Chen College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA
  • Zhi Shi College of Life Science, Jinan University, Guangzhou 510632, PR China
  • Wei-Min Chen College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Zhe Yao College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Dong-Mei Zhang College of Pharmacy, Jinan University, Guangzhou 510632, PR China
  • Wen-Cai Ye College of Pharmacy, Jinan University, Guangzhou 510632, PR China

DOI:

https://doi.org/10.6000/1929-2279.2014.03.01.6

Keywords:

Doxorubicin resistance, ABC transporter, P-glycoprotein, 23-HBA derivative B5H7, HepG2/ADM.

Abstract

 Multidrug resistance (MDR) is the major cause of the failure of cancer chemotherapy. Development of MDR reversers is an important strategy to improve the efficacy of cancer chemotherapy. Here, we have found a morpholine derivative of 23-hydroxybetulinic acid, B5H7, with a reversal effect on MDR cancer cells. Our studies showed that B5H7 enhanced cytotoxicity of doxorubicin, but no cisplatin in MDR cancer cells HepG2/ADM. And we found that B5H7 not only increased the intracellular accumulation of P-glycoprotein substrates doxorubicin and rhodamine123, but also reduced the efflux of rhodamine123 in HepG2/ADM cells. Further studies showed B5H7 did not alter the protein level of P-glycoprotein and it also had no effect on P-glycoprotein ATPase activity. Taken together, we have found that B5H7 could reverse doxorubicin resistance in HepG2/ADM cells by inhibiting the transport function of P-glycoprotein. These findings contribute to developing B5H7 as an adjuvant to anticancer chemotherapy with doxorubicin.

References

Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 27-42. http://dx.doi.org/10.2174/1567201043480036

Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-17.

Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-65.

Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010; 596: 341-58. http://dx.doi.org/10.1007/978-1-60761-416-6_15

Ye WC, Ji NN, Zhao SX, et al. Triterpenoids from Pulsatilla chinensis. Phytochemistry 1996; 42: 799-802.

Ye YY, He DW, Ye WC, et al. The anticancer effect of 23-hydroxyl betulinic acid in vitro. Journal of Southeast University (Medical Science Edition) 2001; 20: 141-4.

Lan P, Wang J, Zhang DM, et al. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives. Eur J Med Chem 2011; 46: 2490-502. http://dx.doi.org/10.1016/j.ejmech.2011.03.038

Zhang DM, Shu C, Chen JJ, et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm 2012; 9: 3147-59. http://dx.doi.org/10.1021/mp300249s

Zhang DM, Li YJ, Shu C, et al. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. Anticancer Drugs 2013; 24: 441-54. http://dx.doi.org/10.1097/CAD.0b013e32835fcc77

Keller RP, Altermatt HJ, Nooter K, et al. SDZ PSC833, a non immunosuppressive cyclosporine: its potency in overcoming P-glycolprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992; 50: 593-7. http://dx.doi.org/10.1002/ijc.2910500418

Canitrot Y, Lautier D. Use of rhodamine 123 for the detection of multidrug resistance, Bull Cancer 1995; 82: 687-97

Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013; 13: 326-46. http://dx.doi.org/10.2174/15680096113139990076

Orlowski S, Mir LM, Belehradek J, et al. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 1996; 15: 515-22.

Shi Z, Tiwari AK, Shukla S, et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71: 3029-41. http://dx.doi.org/10.1158/0008-5472.CAN-10-3820

Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996; 36: 161-83. http://dx.doi.org/10.1146/annurev.pa.36.040196.001113

Srivastava V, Negi AS, Kumar JK, et al. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem 2005; 13: 5892-908.

Lan P, Zhang DM, Chen WM, et al. Advances in the study of structural modifications and biological activities of betulinic acids.Yao Xue Xue Bao 2010; 45: 1339-45.

Constantinides PP, Wasan KM. Lipid formulation strategies for en-hancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies[J]. J Pharm Sci 2007; 96: 235. http://dx.doi.org/10.1002/jps.20780

Li CG, Li ML, Zhou Q, et al. Effects of ?-elemene on phosphatide membrane function and Bcl-2 expression of human bladder carcinoma BIU-87 cells [J]. Chinese Traditional and Herbal Drugs 2007; 38: 886.

Downloads

Published

2014-01-02

How to Cite

Nan Yao, Dao-Lu Liu, Ying-Jie Li, Zhe-Sheng Chen, Zhi Shi, Wei-Min Chen, Zhe Yao, Dong-Mei Zhang, & Wen-Cai Ye. (2014). B5H7, a Morpholine Derivative of 23-Hydroxybetulinic Acid, Reverses Doxorubicin Resistance in HepG2/ADM. Journal of Cancer Research Updates, 3(1),  59–66. https://doi.org/10.6000/1929-2279.2014.03.01.6

Issue

Section

Articles